𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: A meta-analysis

✍ Scribed by Finckh, Axel ;Liang, Matthew H. ;van Herckenrode, Carmen Mugica ;de Pablo, Paola


Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
144 KB
Volume
55
Category
Article
ISSN
0004-3591

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Objective

Although early initiation of disease‐modifying antirheumatic drugs (DMARDs) is effective in controlling short‐term joint damage in individuals with rheumatoid arthritis (RA), the long‐term benefit in disease progression is still controversial. We examined the long‐term benefit of early DMARD initiation on radiographic progression in early RA.

Methods

We identified published and unpublished clinical trials and observational studies from 1966 to September 2004 examining the association between delay to treatment initiation and progressive radiographic joint damage. We included studies of persons with RA disease duration <2 years and DMARD therapy of similar efficacy during followup. The differences in annual rates of radiographic progression between early and delayed therapy were pooled as standardized mean differences (SMDs).

Results

A total of 12 studies met the inclusion criteria. The pooled estimate of effects from these studies demonstrated a significant reduction of radiographic progression in patients treated early (−0.19 SMD, 95% confidence interval [95% CI] −0.34, −0.04), which corresponded to a −33% reduction (95% CI −50, −16) in long‐term progression rates compared with patients treated later. Patients with more aggressive disease seemed to benefit most from early DMARD initiation (P = 0.04).

Conclusion

These results support the existence of a critical period to initiate antirheumatic therapy, a therapeutic window of opportunity early in the course of RA associated with sustained benefit in radiographic progression for up to 5 years. Prompt initiation of antirheumatic therapy in persons with RA may alter the long‐term course of the disease.


📜 SIMILAR VOLUMES


Markers for type II collagen breakdown p
✍ Robert Landewé; Piet Geusens; Maarten Boers; Désirée van der Heijde; Willem Lems 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 157 KB

## Abstract ## Objective To investigate in a randomized clinical trial setting with an aggressive combination‐therapy arm and a mild‐monotherapy arm, whether therapy‐induced changes in urinary C‐terminal crosslinking telopeptide of type I collagen (CTX‐I) and type II collagen (CTX‐II) predict 5‐ye

Similar effects of disease-modifying ant
✍ Niels Graudal; Gesche Jürgens 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 169 KB 👁 1 views

## Abstract ## Objective To define the differences in effects on joint destruction in rheumatoid arthritis (RA) patients between therapy with single and combination disease‐modifying antirheumatic drugs (DMARDs), glucocorticoids, and biologic agents. ## Methods Randomized controlled trials in RA

Impact of initial aggressive drug treatm
✍ Kari Puolakka; Hannu Kautiainen; Timo Möttönen; Pekka Hannonen; Markku Korpela; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 2 views

## Abstract ## Objective To compare the efficacy of therapy with a combination of disease‐modifying antirheumatic drugs (DMARDs) versus therapy with a single DMARD in the prevention of work disability in patients with early rheumatoid arthritis (RA). ## Methods In the Finnish Rheumatoid Arthriti